Skip to content
Checking whether you are signed in

Pfizer Inc.

PFENew York Stock ExchangeFull coverage

Price
Loading your watchlists

Latest dossier

AI-generated

General research and analysis by Moatsight, not personalized investment advice. We show, you decide. Disclaimers

How dossiers are written

Q3 of fiscal year 2026 · Published Nov 7, 2026, 10:41 PM UTC

Pfizer sells prescription medicines and vaccines, and about a quarter of its revenue comes from four drugs (Eliquis, Ibrance, Xtandi and Xeljanz) that lose US exclusivity or face Medicare negotiated prices between 2026 and 2028. In the third quarter of fiscal 2026 revenue was flat at $16.6 billion, but grew 7.3% outside the COVID products, and Pfizer raised its full-year guidance; half of that growth, however, came from a price gain on Eliquis, whose US generics may launch from April 2028. Moatsight estimates revenue of $60.1 billion and free cash flow of $10.9 billion over the next four quarters, and estimates that free cash flow will fall below the dividend in 2028 and 2029. Whether newer products such as Padcev, the Vyndaqel family and the obesity program acquired with Metsera can fill the gap after 2028 is the question that decides the company's value.

Read the dossier

What you pay

FigureAt the close5-yr median5-yr range
P/ENo value: no close yetNo value: no price history
EV/SalesNo value: no close yetNo value: no price history
EV/EBITDANo value: no close yetNo value: no price history
Price/FCFNo value: no close yetNo value: no price history
Market capNo value: no close yet
Net debt and other claims(enterprise value minus market cap)No value: no close yet
Enterprise valueNo value: no close yet

How the business is doing

FigureLast 12 months1-year change1-yearYearly, 3 years8 quarters
Revenue$63.6B+1.3%(better for the company)No value: cannot be derivedEach quarter is listed in the row's details.
Diluted EPS$0.70−59.2%(worse for the company)No value: cannot be derivedEach quarter is listed in the row's details.
Free cash flow$11.8B+13.6%(better for the company)+13.0%Each quarter is listed in the row's details.
Gross margin73.4%0.0 ppNo value: cannot be derivedEach quarter is listed in the row's details.
Operating marginNo value: not in the filingsNo value: not in the filingsNo value: not in the filingsNo value: not in the filings
Net margin6.3%−9.3 pp(worse for the company)No value: cannot be derivedEach quarter is listed in the row's details.
Share count5.751B+0.6%(worse for the company)No value: cannot be derivedEach quarter is listed in the row's details.
How to read these figures
  • Last 12 months: the latest four reported quarters added up, or a figure computed from them. The share count is its latest quarter's average.
  • 1-year change: the last 12 months against the 12 months a year earlier. A margin's change is in percentage points (pp). On a Next 12 months row, it is Moatsight's estimate against the last 12 months.
  • Yearly, 3 years: the yearly rate over the last 3 years, compounded. For a margin, its average change a year in percentage points.
  • 8 quarters: the last 12 months at each of the latest 8 quarter ends, oldest on the left; the dot is the latest. The quarters themselves are on Financials.
  • n/m: not meaningful, such as a rate of change from a loss.
  • Color: a 1-year change in the gain color is better for the company, one in the loss color worse. The caret and the sign show which way it moved, and a row where lower is better says so in its details. Color judges the company's reported results, never its share price or Moatsight's estimates, and no other column is colored.

Price

No closing prices are stored for this listing yet.

Facts

Exchange
New York Stock Exchange · USD
Kind
Common stock
Security
Common Stock